solidbio.com - SLDB Enterprise Value to EBITDA Ratio
Biotech startup Solid Biosciences Inc. (SLDB) focuses on Duchenne muscular dystrophy therapy for a narrow segment of clinics, utilizing accumulated capital from institutional partners to fund research. This chart of stock quotes on GURU.Markets demonstrates an EV/EBITDA of 0.00. A team of gene editing experts leads the project, aiming to implement new medical standards through the support of strategic investors.
SLDB (solidbio.com): analytical breakdowns and indicator data
- current price and projected stock value:
- issuer market value details:
- business book valuation details:
- debt and solvency information:
Debt to Equity Solid Biosciences Inc.|SLDB - Long-Term Liabilities to Capital|Short-Term Debt to Equity Solid Biosciences|SLDB - Company Total Debt Obligations|Debts to Book Capitalization Solid Corp|SLDB - Company Long-Term Liabilities|Company Short-Term Debts Solid Biosciences|Quick Ratio solidbio.com
- financial results and valuation multiples details:
SLDB - Company Net Income|Expected Profit Solid Biosciences Inc.|SLDB - Price to Earnings Multiple|Forward P/E Multiple Solid Biosciences Inc.|SLDB - Price/Earnings to Growth Multiple|EV/EBITDA Multiple Solid Corp|SLDB - Profit before interest, taxes and amortization|Earnings per share for the last twelve months Solid Biosciences|SLDB - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months solidbio.com|SLDB - Earnings per share increase in current year|Earnings growth forecast for next year Solid Biosciences Inc.
Comprehensive company analysis:Solid Bio SLDB
The scale of the Solid Biosciences Inc. (SLDB) gene therapy ecosystem is revealed through the EV/EBITDA debt and operational load valuation metric. This multiple correlates the total enterprise value with its operating profit before depreciation and interest. The calculation determines cash flow generation efficiency relative to accumulated debt. Given the FDA's strict control over vector toxicity, the indicator's dynamics reflect the market's pricing of the drug's commercial success.
Competitors of Solid Biosciences Inc. (SLDB)
EV/EBITDA Multiple TEM (tempus.com)|QGEN: Enterprise Value to Operating Income Before Depreciation|IONS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RGEN (repligen.com)|RNA: EV/EBITDA Multiple|CRSP (CRISPR Therapeutics Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WGS (Sema4) - EV/EBITDA Multiple|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|SRPT - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience, Inc. TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics Inc (TXG)|Intellia - EV/EBITDA Multiple|Stoke Corp (STOK) - Enterprise Value to EBITDA Ratio|BLFS: EV/EBITDA Multiple|WVE - Total Company Value to Operating Income Before Depreciation Ratio|MAZE (Maze Therapeutics) - EV/EBITDA Multiple|Company Value to EBITDA Sionna Therapeutics, Inc. SION|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|Taysha Corp - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple QURE (uniQure N.V.)|MGTX - Enterprise Value to EBITDA Ratio|REGENXBIO - EV/EBITDA Multiple|Company Value to EBITDA Ocugen Inc|Pacific Biosciences of California (PACB) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|BNTC - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio DSGN|RCKT: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple FDMT|Total Company Value to Operating Income Before Depreciation Ratio lexeotx.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Korro Bio KRRO|EDIT: Enterprise Value to Operating Income Before Depreciation|Silence Therapeutics - EV/EBITDA Multiple|ProQR Therapeutics N.V. (PRQR) - Enterprise Value to EBITDA Ratio|CDXS (codexis.com) - Enterprise Value to EBITDA Ratio|SGMO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Biotechnology, Inc.|Metagenomi Therapeutics (MGX) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Precision BioSciences (DTIL)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GBIO (generationbio.com)|EV/EBITDA Multiple BOLD (Boundless Bio)|XCUR: Enterprise Value to Operating Income Before Depreciation|Celsion Corporation - EV/EBITDA Multiple|PHIO: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|MBIO: EV/EBITDA Multiple|Enterprise Value to Operating Income Before Depreciation RNAZ|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bionano Genomics Inc.|Enterprise Value to Operating Income Before Depreciation APDN (Applied DNA Sciences Inc)|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple immunoprecise.com (IPA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Omega Therapeutics OMGA|Total Company Value to Operating Income Before Depreciation Ratio singulargenomics.com (OMIC)|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Syros Pharmaceuticals Inc.|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|TCON (TRACON Pharmaceuticals, Inc) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|UBX (Unity Biotechnology) - EV/EBITDA Multiple
